Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression

Laboratory Investigation

Volumn 84, Issue 11, 2004, Pages 1512-1519

  Zhao, Wei Li ^a,e   Mourah, Samia ^b   Mounier, Nicolas ^a   Leboeuf, Christophe ^a   Daneshpouy, Marjan Ertault ^a   Legrès, Luc ^a   Meignin, Veronique ^a   Oksenhendler, Eric ^c   Le Maignin, Christine ^d   Calvo, Fabien ^b   Brière, Josette ^a   Gisselbrecht, Christian ^a   Janin, Anne ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b Laboratoire de Pharmacologie   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Angioimmunoblastic T cell lymphoma; Vascular endothelial growth factor A

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ANGIOGENESIS; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; BONE MARROW; CANCER GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DYSTROPHY; ENDOTHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHOMA; LYMPHOMA CELL; MALE; MICROVASCULATURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; T CELL LYMPHOMA; TISSUE SECTION; TUMOR ANGIOGENESIS; VEGF A GENE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPH NODES; LYMPHOMA, T-CELL; MALE; MICROCIRCULATION; MICRODISSECTION; MIDDLE AGED; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 8344254359     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700145     Document Type: Article

References (31)

1. Dvorak HF. Rous-Whipple award lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747-1757.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
3. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-11954.
4. de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991.
5. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-1586.
6. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
7. Gee MS, Procopio WN, Makonnen S, et al. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003;162:183-193.
8. Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59: 728-733.
9. Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 2002;40:253-260.
10. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90:3167-3172.
11. Fusetti L, Pruneri G, Gobbi A, et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 2000;60:2527-2534.
12. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1974;1:1070-1073.
13. Pangalis GA, Moran EM, Nathwani BN, et al. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer 1983;52:318-321.
14. Harris NL, Jaffe ES, Diebold J, et al. Lymphoma classification-from controversy to consensus: the R. E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 2000;11:3-10.
15. Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999;32:545-552.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162: 156-159.
17. Wellmann S, Taube T, Paal K, et al. Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by Light-Cycler technology. Clin Chem 2001;47:654-660.
18. Menashi S, Serova M, Ma L, et al. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res 2003;63:7575-7580.
19. Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997;183:44-50.
20. Detmar M, Brown LF, Berse B, et al. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997;108: 263-268.
21. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-3721.
22. de Bont ES, Fidler V, Meeuwsen T, et al. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002;8:2856-2861.
23. Koomagi R, Zintl F, Sauerbrey A, et al. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 2001;7: 3381-3384.
24. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000;89:475-483.
25. Tokunaga T, Oshika Y, Abe Y, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998;77:998-1002.
26. Hayashibara T, Yamada Y, Miyanishi T, et al. Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res 2001;7:2719-2726.
27. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-435.
28. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-840.
29. Pavco PA, Bouhana KS, Gallegos AM, et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000;6: 2094-2103.
30. Zhang L, Yang N, Park JW, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-3412.
31. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.